Chengjie Li

Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study.

Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study.

Journal: Journal for immunotherapy of cancer

Published: January 28, 2026

Efficacy and safety of immune checkpoint inhibitors in patients with high microsatellite instability/mismatch repair-deficient advanced cholangiocarcinoma: A propensity score-matched study.

Efficacy and safety of immune checkpoint inhibitors in patients with high microsatellite instability/mismatch repair-deficient advanced cholangiocarcinoma: A propensity score-matched study.

Journal: JHEP reports : innovation in hepatology

Published: December 11, 2025

Effectiveness and conversion outcomes of immune checkpoint inhibitors combined with lenvatinib and GEMOX chemotherapy as first-line treatment for advanced gallbladder cancer: A multicenter study.

Effectiveness and conversion outcomes of immune checkpoint inhibitors combined with lenvatinib and GEMOX chemotherapy as first-line treatment for advanced gallbladder cancer: A multicenter study.

Journal: Chinese medical journal

Published: December 02, 2025

Postoperative adjuvant TACE combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma with high recurrence risks: a multicenter retrospective study.

Postoperative adjuvant TACE combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma with high recurrence risks: a multicenter retrospective study.

Journal: BMC cancer

Published: November 01, 2025

Peripheral PD-1⁺ T cell signatures predict immunotherapy response and survival in hepatobiliary cancers.

Peripheral PD-1⁺ T cell signatures predict immunotherapy response and survival in hepatobiliary cancers.

Journal: Translational research : the journal of laboratory and clinical medicine

Published: October 26, 2025

Current status of management of immune-related adverse events and practical needs for oncologist education.

Current status of management of immune-related adverse events and practical needs for oncologist education.

Journal: Cancer biology & medicine

Published: September 24, 2025

Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study.

Local-regional therapy plus ICIs, chemotherapy, and lenvatinib versus ICIs plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter study.

Journal: Cancer immunology, immunotherapy : CII

Published: August 28, 2025

AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma.

AARS1 promotes tumor progression and immune evasion via ATF6 lactylation-mediated tryptophan metabolism in hepatocellular carcinoma.

Journal: Cell metabolism

Published: August 14, 2025

Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer.

Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: August 07, 2025

Lenvatinib enhances the response of biliary tract cancer to anti-HER2 therapy.

Lenvatinib enhances the response of biliary tract cancer to anti-HER2 therapy.

Journal: Signal transduction and targeted therapy

Published: July 31, 2025

Local-regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study.

Local-regional therapy combined with immune checkpoint inhibitors and lenvatinib versus immune checkpoint inhibitors plus chemotherapy in advanced intrahepatic cholangiocarcinoma: a multicenter cohort study.

Journal: Cancer immunology, immunotherapy : CII

Published: May 27, 2025

Global research landscape and trends of immunotherapy in biliary tract cancers.

Global research landscape and trends of immunotherapy in biliary tract cancers.

Journal: Chinese medical journal

Published: May 08, 2025

Showing 1-12 of 19

Last Updated: 09/26/2026